A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer

Clinical trial NCT02207465 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT02207465
Sponsor: Abramson Cancer Center at Penn Medicine
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy Borderline Resectable Pancreatic Cancer Treated With Chemoradiotherapy

Start date: 2014-07-01
Primary completion: 2026-12-01
Enrollment: 42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.